Expertise in
6
conditions

Stefan W. Krause

Uniklinikum Erlangen
Erlangen, BY, DE 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
6
conditions
Uniklinikum Erlangen
Erlangen, BY, DE 

Overview

Stefan Krause practices in Erlangen, Germany. Mr. Krause is highly rated in 6 conditions, according to our data. His top areas of expertise are Leukemia, Chronic Myelogenous Leukemia (CML), Acute Myeloid Leukemia (AML), Acute Erythroid Leukemia (AEL), and Bone Marrow Transplant.

His clinical research consists of co-authoring 139 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender

Male

Locations

Uniklinikum Erlangen
Erlangen, BY, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Autologous Transplantation After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma - a Randomized European Mcl Network Trial
Autologous Transplantation After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma - a Randomized European Mcl Network Trial
Enrollment Status: Recruiting
Publish Date: December 19, 2017
Intervention Type: Drug
Study Drugs: R-CHOP/R-DHAP, Ibrutinib (Induction), ASCT Conditioning, Ibrutinib (Maintenance)
Study Phase: Phase 3
Evaluation of the Impact of Remission Induction Chemotherapy Prior to Allogeneic Stem Cell Transplantation in Relapsed and Poor-response Patients With AML
Evaluation of the Impact of Remission Induction Chemotherapy Prior to Allogeneic Stem Cell Transplantation in Relapsed and Poor-response Patients With AML
Enrollment Status: Completed
Publish Date: January 19, 2024
Intervention Type: Drug
Study Phase: Phase 3
Treatment Optimization of Newly Diagnosed Ph/BCR-ABL Positive Patients With Chronic Myeloid Leukemia (CML) in Chronic Phase With Nilotinib vs. Nilotinib Plus Interferon Alpha Induction and Nilotinib or Interferon Alpha Maintenance Therapy
Treatment Optimization of Newly Diagnosed Ph/BCR-ABL Positive Patients With Chronic Myeloid Leukemia (CML) in Chronic Phase With Nilotinib vs. Nilotinib Plus Interferon Alpha Induction and Nilotinib or Interferon Alpha Maintenance Therapy
Enrollment Status: Completed
Publish Date: May 10, 2023
Intervention Type: Drug
Study Drugs: Peginterferon ?2b, Nilotinib
Study Phase: Phase 3
Efficacy and Safety of Pegylated Proline Interferon Alpha 2b (AOP2014) in Maintaining Deep Molecular Remissions in Patients With Chronic Myeloid Leukemia (CML) Who Discontinue ABL-Kinase Inhibitor Therapy - a Randomized Phase III, Multicenter Trial With Post-study Follow-up
Efficacy and Safety of Pegylated Proline Interferon Alpha 2b (AOP2014) in Maintaining Deep Molecular Remissions in Patients With Chronic Myeloid Leukemia (CML) Who Discontinue ABL-Kinase Inhibitor Therapy - a Randomized Phase III, Multicenter Trial With Post-study Follow-up
Enrollment Status: Completed
Publish Date: March 31, 2023
Intervention Type: Drug, Other
Study Drug: AOP2014 / Pegylated-Proline-Interferon Alpha-2b
Study Phase: Phase 3
A Single-arm Phase II Trial to Assess the Efficacy of Midostaurin (PKC412) Added to Standard Primary Therapy in Patients With Newly Diagnosed c-KIT or FLT3-ITD Mutated t(8;21) AML
A Single-arm Phase II Trial to Assess the Efficacy of Midostaurin (PKC412) Added to Standard Primary Therapy in Patients With Newly Diagnosed c-KIT or FLT3-ITD Mutated t(8;21) AML
Enrollment Status: Completed
Publish Date: August 06, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 4 Less Clinical Trials

139 Total Publications

Evidence-based AGIHO guideline update on prophylaxis of infectious complications with granulocyte-stimulating factors (G-CSF) for the treatment of adult patients with cancer.
Evidence-based AGIHO guideline update on prophylaxis of infectious complications with granulocyte-stimulating factors (G-CSF) for the treatment of adult patients with cancer.
Journal: European journal of cancer (Oxford, England : 1990)
Published: December 23, 2025

Frequently Asked Questions about Stefan W. Krause

Is Stefan W. Krause a top-rated expert for Leukemia?

MediFind is an objective health platform that identifies experts based on real-world data. Stefan W. Krause is classified as an Elite expert for Leukemia, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Stefan W. Krause participate in research or clinical trials?

Yes. Stefan W. Krause has published 139 articles and abstracts on conditions like Leukemia. You can view a list of Stefan W. Krause's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Krause's expertise for a condition
ConditionClose
View All 21 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile